Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression

被引:149
作者
Grotzer, MA [1 ]
Eggert, A [1 ]
Zuzak, TJ [1 ]
Janss, AJ [1 ]
Marwaha, S [1 ]
Wiewrodt, BR [1 ]
Ikegaki, N [1 ]
Brodeur, GM [1 ]
Phillips, PC [1 ]
机构
[1] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
关键词
TRAIL; PNET; medulloblastoma; apoptosis;
D O I
10.1038/sj.onc.1203816
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in adult malignant glioma and various other human solid tumor models but not in normal tissues. To characterize the TRAIL death pathway in childhood primitive neuroectodermal brain tumor (PNET), 8 human PNET cell lines were tested for TRAIL-induced apoptosis, TRAIL-sensitivity of the PNET cell lines was correlated with mRNA expression levels of TRAIL, its agonistic (TRAIL-R1, TRAIL-R2) and antagonistic (TRAIL-R3, TRAIL-R4) receptors, cellular FLICE-like inhibitory protein (cFLIP), caspase-3 and caspase-8, Three of 8 PNET cell lines tested were susceptible to TRAIL-induced apoptosis, Sensitivity to TRAIL-induced apoptosis did not correlate with mRNA expression of TRAIL receptors or cFLIP, However, all TRAIL-sensitive PNET cell lines expressed caspase-8 mRNA and protein, while none of the five TRAIL-resistant PNET cell lines expressed caspase-8 protein. Treatment with the methyltransferase inhibitor 5-aza-2'-deoxycytidine restored mRNA expression of caspase-8 and TRAIL-sensitivity in formerly TRAIL-resistant PNET cells, suggesting that gene methylation inhibits caspase-8 transcription in these cells. We conclude, that loss of caspase-8 mRNA is an important mechanism of TRAIL-resistance in PNET cells. Treatment with recombinant soluble TRAIL, possibly in combination with methyltransferase inhibitors, represents a promising therapeutic approach for PNET that deserves further investigation.
引用
收藏
页码:4604 / 4610
页数:7
相关论文
共 41 条
[1]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[2]   TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].
Bodmer, JL ;
Holler, N ;
Reynard, S ;
Vinciguerra, P ;
Schneider, P ;
Juo, P ;
Blenis, J ;
Tschopp, J .
NATURE CELL BIOLOGY, 2000, 2 (04) :241-243
[3]   Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family [J].
DegliEsposti, MA ;
Smolak, PJ ;
Walczak, H ;
Waugh, J ;
Huang, CP ;
DuBose, RF ;
Goodwin, RG ;
Smith, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1165-1170
[4]   Relative quantitative RT-PCR protocol for TrkB expression in neuroblastoma using GAPD as an internal control [J].
Eggert, A ;
Brodeur, GM ;
Ikegaki, N .
BIOTECHNIQUES, 2000, 28 (04) :681-+
[5]   Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia [J].
Estrov, Z ;
Thall, PF ;
Talpaz, M ;
Estey, EH ;
Kantarjian, HM ;
Andreeff, M ;
Harris, D ;
Van, Q ;
Walterscheid, M ;
Kornblau, SM .
BLOOD, 1998, 92 (09) :3090-3097
[6]  
Faderl S, 1999, CLIN CANCER RES, V5, P4041
[7]   Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells [J].
Friesen, C ;
Herr, I ;
Krammer, PH ;
Debatin, KM .
NATURE MEDICINE, 1996, 2 (05) :574-577
[8]  
Fulda S, 1997, CANCER RES, V57, P3823
[9]   IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION [J].
GAVRIELI, Y ;
SHERMAN, Y ;
BENSASSON, SA .
JOURNAL OF CELL BIOLOGY, 1992, 119 (03) :493-501
[10]   Structure and chromosome localization of the human CASP8 gene [J].
Grenet, J ;
Teitz, T ;
Wei, T ;
Valentine, V ;
Kidd, VJ .
GENE, 1999, 226 (02) :225-232